Zai Lab Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 2,175

Employees

  • Stock Symbol
  • 09688

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.09
  • (As of Monday Closing)

Zai Lab General Information

Description

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building 1, 4 Floor, Jinchuang Plaza
  • 4560 Jinke Road, Pudong
  • Shanghai, 201210
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Delivery
Stock Exchange
HKG
Vertical(s)
Oncology
Corporate Office
  • Building 1, 4 Floor, Jinchuang Plaza
  • 4560 Jinke Road, Pudong
  • Shanghai, 201210
  • China
+86 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zai Lab Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.09 $3.02 $1.35 - $3.32 $3.07B 996M 3.85M -$0.31

Zai Lab Financials Summary

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,113,373 1,903,072 1,991,307 4,704,230
Revenue 322,711 266,719 215,040 144,312
EBITDA (325,858) (365,388) (449,420) (699,117)
Net Income (298,329) (334,620) (443,286) (704,471)
Total Assets 987,368 1,036,295 1,220,140 1,609,956
Total Debt 83,682 15,151 20,393 15,540
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zai Lab Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zai Lab‘s full profile, request access.

Request a free trial

Zai Lab Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprie
Biotechnology
Shanghai, China
2,175 As of 2023

Suzhou, China
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zai Lab Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alphamab Oncology Formerly VC-backed Suzhou, China
Xenetic Bioscience Corporation Framingham, MA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
BeiGene Formerly PE-Backed Cambridge, MA
You’re viewing 5 of 41 competitors. Get the full list »

Zai Lab Patents

Zai Lab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022400921-A1 Ccr8 antigen binding unit and uses thereof Pending 02-Dec-2021
CA-3239784-A1 Ccr8 antigen binding unit and uses thereof Pending 02-Dec-2021
EP-4441098-A1 Ccr8 antigen binding unit and uses thereof Pending 02-Dec-2021
EP-4342899-A1 Salt form and crystal form of heterocyclic substituted purinone derivative Inactive 19-May-2021
US-20240254145-A1 Salt form and crystal form of heterocyclic substituted purinone derivative Pending 19-May-2021 C07D519/00
To view Zai Lab’s complete patent history, request access »

Zai Lab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zai Lab Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zai Lab‘s full profile, request access.

Request a free trial

Zai Lab Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Jing Medicine Technology 05-Dec-2017 Drug Discovery
Caidya 01-Dec-2016 Early Stage VC Laboratory Services (Healthcare)
To view Zai Lab’s complete investments history, request access »

Zai Lab ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

25.59 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,009

Rank

Percentile

Pharmaceuticals

Industry

of 909

Rank

Percentile

Biotechnology

Subindustry

of 404

Rank

Percentile

To view Zai Lab’s complete esg history, request access »

Zai Lab FAQs

  • When was Zai Lab founded?

    Zai Lab was founded in 2014.

  • Where is Zai Lab headquartered?

    Zai Lab is headquartered in Shanghai, China.

  • What is the size of Zai Lab?

    Zai Lab has 2,175 total employees.

  • What industry is Zai Lab in?

    Zai Lab’s primary industry is Biotechnology.

  • Is Zai Lab a private or public company?

    Zai Lab is a Public company.

  • What is Zai Lab’s stock symbol?

    The ticker symbol for Zai Lab is 09688.

  • What is the current stock price of Zai Lab?

    As of 04-Nov-2024 the stock price of Zai Lab is $3.09.

  • What is the current market cap of Zai Lab?

    The current market capitalization of Zai Lab is $3.07B.

  • What is Zai Lab’s current revenue?

    The trailing twelve month revenue for Zai Lab is $323M.

  • Who are Zai Lab’s competitors?

    Alphamab Oncology, Xenetic Bioscience, Sutro Biopharma, Dicerna Pharmaceuticals, and BeiGene are some of the 41 competitors of Zai Lab.

  • What is Zai Lab’s annual earnings per share (EPS)?

    Zai Lab’s EPS for 12 months was -$0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »